Legend Biotech Corporation (NASDAQ: LEGN) announced clinical trial data for LB2501, an investigational in vivo CAR-T cell therapy targeting CD19/CD20 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE